Abstract

Although inflammation plays critical roles in the development of atherosclerosis, its regulatory mechanisms remain incompletely understood. Perivascular adipose tissue (PVAT) has been reported to undergo inflammatory changes in response to vascular injury. Here, we show that vascular injury induces the beiging (brown adipose tissue-like phenotype change) of PVAT, which fine-tunes inflammatory response and thus vascular remodeling as a protective mechanism. In a mouse model of endovascular injury, macrophages accumulate in PVAT, causing beiging phenotype change. Inhibition of PVAT beiging by genetically silencing PRDM16, a key regulator to beiging, exacerbates inflammation and vascular remodeling following injury. Conversely, activation of PVAT beiging attenuates inflammation and pathological vascular remodeling. Single-cell RNA sequencing reveals that beige adipocytes abundantly express neuregulin 4 (Nrg4) which critically regulate alternative macrophage activation. Importantly, significant beiging is observed in the diseased aortic PVAT in patients with acute aortic dissection. Taken together, vascular injury induces the beiging of adjacent PVAT with macrophage accumulation, where NRG4 secreted from the beige PVAT facilitates alternative activation of macrophages, leading to the resolution of vascular inflammation. Our study demonstrates the pivotal roles of PVAT in vascular inflammation and remodeling and will open a new avenue for treating atherosclerosis.

Perivascular adipose tissue (PVAT) has been reported to undergo inflammatory changes in response to vascular injury. Here, the authors show that vascular injury induces the beiging (brown adipose tissue-like phenotype change) of PVAT, which fine-tunes inflammatory response as a protective mechanism.

Details

Title
Beiging of perivascular adipose tissue regulates its inflammation and vascular remodeling
Author
Adachi, Yusuke 1   VIAFID ORCID Logo  ; Ueda, Kazutaka 2   VIAFID ORCID Logo  ; Nomura, Seitaro 3 ; Ito, Kaoru 4   VIAFID ORCID Logo  ; Katoh, Manami 3   VIAFID ORCID Logo  ; Katagiri, Mikako 2   VIAFID ORCID Logo  ; Yamada, Shintaro 3 ; Hashimoto, Masaki 2 ; Zhai, Bowen 2 ; Numata, Genri 2   VIAFID ORCID Logo  ; Otani, Akira 2 ; Hinata, Munetoshi 5 ; Hiraike, Yuta 6   VIAFID ORCID Logo  ; Waki, Hironori 6 ; Takeda, Norifumi 2 ; Morita, Hiroyuki 2 ; Ushiku, Tetsuo 5 ; Yamauchi, Toshimasa 6 ; Takimoto, Eiki 2 ; Komuro, Issei 2   VIAFID ORCID Logo 

 Graduate School of Medicine, The University of Tokyo, Department of Cardiovascular Medicine, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X); The University of Tokyo, Department of Advanced Clinical Science and Therapeutics, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X) 
 Graduate School of Medicine, The University of Tokyo, Department of Cardiovascular Medicine, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X) 
 Graduate School of Medicine, The University of Tokyo, Department of Cardiovascular Medicine, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X); The University of Tokyo, Genome Science Division, Research Center for Advance Science and Technology, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X) 
 RIKEN Center for Integrative Medical Sciences, Laboratory for Cardiovascular Genomics and Informatics, Yokohama, Japan (GRID:grid.509459.4) (ISNI:0000 0004 0472 0267) 
 The University of Tokyo, Department of Pathology, Graduate School of Medicine, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X) 
 The University of Tokyo, Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2711089978
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.